Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

por Schöffski, Patrick, Tan, Daniel S W, Martín, Miguel, Ochoa-de-Olza, María, Sarantopoulos, John, Carvajal, Richard D, Kyi, Chrisann, Esaki, Taito, Prawira, Amy, Akerley, Wallace, De Braud, Filippo, Hui, Rina, Zhang, Tian, Soo, Ross A, Maur, Michela, Weickhardt, Andrew, Krauss, Jürgen, Deschler-Baier, Barbara, Lau, Allen, Samant, Tanay S, Longmire, Tyler, Chowdhury, Niladri Roy, Sabatos-Peyton, Catherine A, Patel, Nidhi, Ramesh, Radha, Hu, Tiancen, Carion, Ana, Gusenleitner, Daniel, Yerramilli-Rao, Padmaja, Askoxylakis, Vasileios, Kwak, Eunice L, Hong, David S
Publicado 2022